Mark Munch Sells 7,000 Shares of Bruker (NASDAQ:BRKR) Stock

Bruker Corporation (NASDAQ:BRKR) VP Mark Munch sold 7,000 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $55.00, for a total value of $385,000.00. Following the sale, the vice president owned 128,443 shares of the company’s stock, valued at approximately $7,064,365. This represents a 5.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Bruker Stock Performance

NASDAQ BRKR opened at $49.14 on Thursday. The firm has a 50-day moving average price of $46.82 and a two-hundred day moving average price of $39.94. Bruker Corporation has a 12-month low of $28.53 and a 12-month high of $63.13. The company has a market capitalization of $7.47 billion, a P/E ratio of -307.13, a P/E/G ratio of 6.56 and a beta of 1.17. The company has a quick ratio of 0.91, a current ratio of 1.85 and a debt-to-equity ratio of 0.81.

Bruker (NASDAQ:BRKR) last released its earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The firm had revenue of $860.50 million during the quarter, compared to the consensus estimate of $847.40 million. During the same period in the prior year, the company posted $0.60 EPS. The company’s revenue was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Analysts anticipate that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 2nd. Shareholders of record on Monday, December 8th were given a $0.05 dividend. The ex-dividend date was Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker’s dividend payout ratio (DPR) is currently -125.00%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Zacks Research upgraded Bruker from a “strong sell” rating to a “hold” rating in a report on Monday, December 8th. Rothschild Redb raised shares of Bruker to a “strong-buy” rating in a report on Thursday, November 20th. Wolfe Research raised shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price target for the company in a research note on Wednesday, December 10th. TD Cowen lifted their price target on shares of Bruker from $42.00 to $53.00 and gave the stock a “hold” rating in a report on Wednesday, January 7th. Finally, Rothschild & Co Redburn assumed coverage on shares of Bruker in a research note on Thursday, November 20th. They issued a “buy” rating and a $60.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Bruker presently has an average rating of “Hold” and an average target price of $52.29.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of BRKR. Nisa Investment Advisors LLC increased its holdings in shares of Bruker by 377.5% during the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 487 shares in the last quarter. Huntington National Bank increased its stake in Bruker by 750.0% during the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 645 shares in the last quarter. Spire Wealth Management acquired a new position in Bruker during the second quarter worth $32,000. Allworth Financial LP raised its holdings in Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after buying an additional 257 shares during the last quarter. Finally, Parallel Advisors LLC lifted its stake in shares of Bruker by 63.0% in the second quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock valued at $37,000 after buying an additional 347 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.